Related Experiment Video
Updated: Apr 28, 2026

In vitro Organoid Culture of Primary Mouse Colon Tumors
Published on: May 17, 2013
PKCdelta-mediated regulation of FLIP expression in human colon cancer cells
Qingding Wang1, Xiaofu Wang, Yuning Zhou
1Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555, USA.
Abstract:
FLICE-like inhibitory protein (FLIP), a naturally occurring caspase-inhibitory protein that lacks the critical cysteine domain necessary for catalytic activity, is a negative regulator of Fas-induced apoptosis. Decreased FLIP levels sensitize tumor cells to Fas- and TRAIL-mediated apoptosis; however, the cellular mechanisms regulating FLIP expression have not been defined. Here, we examined the roles of the PKC and NF-kappaB pathway in the regulation of FLIP in human colon cancers. FLIP mRNA levels were increased in Caco-2 cells by treatment with PMA; actinomycin D completely inhibited the induction of FLIP by PMA, indicating transcriptional regulation. PKC inhibitors Gö6983 and Ro-31-8220 blocked PMA-stimulated FLIP expression. Pretreatment with the PKCdelta-selective inhibitor rottlerin or transfection with PKCdelta siRNA inhibited PMA-induced FLIP expression, which identifies a role for PKCdelta in FLIP induction. Treatment with the proteasome inhibitor, MG132, or the NF-kappaB inhibitor (e.g., PDTC and gliotoxin), or overexpression of the superrepressor of IkappaB-alpha inhibited PMA-induced upregulation of FLIP. Moreover, PMA-induced NF-kappaB transactivation was blocked by GF109203x. In conclusion, our results demonstrate a critical role for PKCdelta/NF-kappaB in the regulation of FLIP in human colon cancer cells.
Insights
This study reveals that protein kinase C delta (PKCdelta) and NF-kappaB signaling pathways regulate FLICE-like inhibitory protein (FLIP) expression in human colon cancer cells, impacting apoptosis.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- FLICE-like inhibitory protein (FLIP) is a key regulator of apoptosis.
- FLIP's role in sensitizing tumor cells to apoptosis is known, but its regulatory mechanisms are unclear.
- Understanding FLIP regulation is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the roles of Protein Kinase C (PKC) and Nuclear Factor kappa B (NF-kappaB) pathways in regulating FLIP expression.
- To elucidate the cellular mechanisms controlling FLIP levels in human colon cancer.
Main Methods:
- Utilized Caco-2 cells for experiments.
- Administered phorbol 12-myristate 13-acetate (PMA) to induce FLIP expression.
- Employed PKC inhibitors (Gö6983, Ro-31-8220, rottlerin), actinomycin D, proteasome inhibitor (MG132), and NF-kappaB inhibitors (PDTC, gliotoxin).
- Performed PKCdelta siRNA transfection and IkappaB-alpha superrepressor overexpression.
- Assessed NF-kappaB transactivation.
Main Results:
- PMA treatment increased FLIP mRNA levels, indicating transcriptional regulation.
- PKC inhibitors and PKCdelta-specific interventions blocked PMA-induced FLIP expression.
- Inhibition of proteasome and NF-kappaB pathways, along with IkappaB-alpha overexpression, suppressed PMA-induced FLIP upregulation.
- PKC signaling influenced NF-kappaB transactivation.
Conclusions:
- PKCdelta plays a critical role in inducing FLIP expression.
- The NF-kappaB pathway is essential for the upregulation of FLIP.
- These findings highlight the PKCdelta/NF-kappaB axis as a key regulator of FLIP in human colon cancer.
Related Concept Videos
Negative Regulator Molecules
Cell Specific Gene Expression
Inhibition of Cdk Activity
Abnormal Proliferation
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

